Evaluation of Diagnostic Accuracy of [68Ga]Ga-PSMA-11 PET/CT in Primary Staging of Intermediate and High Risk Prostatic Cancer in Men Newly Diagnosed
Latest Information Update: 10 Mar 2022
Price :
$35 *
At a glance
- Drugs Gallium (68Ga) gozetotide (Primary)
- Indications Prostate cancer
- Focus Diagnostic use
- Acronyms PSMA-PROSTAPET
- 10 Mar 2022 This trial has been discontinued in Italy(End date 28 July 2020), according to European Clinical Trials Database record.
- 16 Sep 2020 Planned End Date changed from 20 Jul 2024 to 20 Sep 2024.
- 16 Sep 2020 Planned primary completion date changed from 20 Jul 2024 to 20 Sep 2024.